Clinical trial
A Long-term Follow-Up Study to Evaluate the Safety and Efficacy of Suprachoroidal Administration of RGX-314 for Diabetic Retinopathy With and Without Center Involved-Diabetic Macular Edema
NCT05296447 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Long-term Follow-Up Study to Evaluate the Safety and Efficacy of Suprachoroidal Administration of RGX-314 for Diabetic Retinopathy With and Without Center Involved-Diabetic Macular Edema
- Lead sponsor
- AbbVie
- Phase
- Phase 2
- Overall status
- Enrolling by invitation
- Start date
- April 4, 2022
- Completion date
- June 30, 2031
- Enrollment
- 100 (estimated)
- Sites
- 20
Conditions
As the registry lists them; a condition with its own page is linked.
diabetic retinopathy, dr